HTA9 A Matching-Adjusted Indirect Comparison (MAIC) of Rucaparib vs. Niraparib in the Maintenance Treatment of Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer (aOC) After Response to First-Line Platinum-Based Chemotherapy